Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs
Public ClinicalTrials.gov record NCT00791895. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) Titrate-To-Target: An Observational Study of the Efficacy of NovoLog® Mix 70/30 in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets on OADs With / Without Once Daily Basal Insulin Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the effectiveness of biphasic insulin aspart 30 in type 2 diabetics not achieving blood sugar levels when treated with oral anti-diabetics drugs (OADs) with or without basal insulin therapy.
Study identification
- NCT ID
- NCT00791895
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 26, 2003 (Actual)
- Primary completion
- Oct 31, 2004 (Actual)
- Completion
- Nov 29, 2004 (Actual)
- Last update posted
- Feb 24, 2017
2003 – 2004
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Phoenix | Arizona | 85006 | — |
| Novo Nordisk Investigational Site | La Jolla | California | 92093-0694 | — |
| Novo Nordisk Investigational Site | La Jolla | California | 92093-0831 | — |
| Novo Nordisk Investigational Site | DeLand | Florida | 32720 | — |
| Novo Nordisk Investigational Site | Wichita | Kansas | 67205 | — |
| Novo Nordisk Investigational Site | Omaha | Nebraska | 68114 | — |
| Novo Nordisk Investigational Site | Albany | New York | 12206 | — |
| Novo Nordisk Investigational Site | Cleveland | Ohio | 44115 | — |
| Novo Nordisk Investigational Site | Medford | Oregon | 97504 | — |
| Novo Nordisk Investigational Site | Memphis | Tennessee | 38119 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75231 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | — |
| Novo Nordisk Investigational Site | Ogden | Utah | 84403 | — |
| Novo Nordisk Investigational Site | Renton | Washington | 98057 | — |
| Novo Nordisk Investigational Site | Milwaukee | Wisconsin | 53209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00791895, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00791895 live on ClinicalTrials.gov.